1. Home
  2. NGNE vs INVZ Comparison

NGNE vs INVZ Comparison

Compare NGNE & INVZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neurogene Inc.

NGNE

Neurogene Inc.

HOLD

Current Price

$20.61

Market Cap

327.8M

Sector

Health Care

ML Signal

HOLD

Logo Innoviz Technologies Ltd. Ordinary shares

INVZ

Innoviz Technologies Ltd. Ordinary shares

HOLD

Current Price

$0.95

Market Cap

273.5M

ML Signal

HOLD

Company Overview

Basic Information
Metric
NGNE
INVZ
Founded
2003
2016
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Auto Parts:O.E.M.
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
327.8M
273.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
NGNE
INVZ
Price
$20.61
$0.95
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
3
Target Price
$38.50
$3.10
AVG Volume (30 Days)
188.3K
4.9M
Earning Date
11-13-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$48,442,000.00
Revenue This Year
N/A
$146.75
Revenue Next Year
N/A
$53.30
P/E Ratio
N/A
N/A
Revenue Growth
N/A
46.09
52 Week Low
$6.88
$0.48
52 Week High
$37.27
$3.14

Technical Indicators

Market Signals
Indicator
NGNE
INVZ
Relative Strength Index (RSI) 47.11 33.93
Support Level $19.28 $0.84
Resistance Level $22.99 $0.97
Average True Range (ATR) 1.44 0.08
MACD 0.32 -0.01
Stochastic Oscillator 40.15 24.21

Price Performance

Historical Comparison
NGNE
INVZ

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

About INVZ Innoviz Technologies Ltd. Ordinary shares

Innoviz Technologies Ltd is a provider of solid-state LiDAR and perception solutions that feature technological breakthroughs across core components and bring enhanced vision and superior performance to enable safe autonomous driving at a mass scale. The company provides a complete and comprehensive solution for OEMs and Tier-1 partners that are developing and marketing autonomous driving vehicles to the passenger cars and other relevant markets, such as robotaxis, shuttles, delivery vehicles, buses and trucks and other industries that require 3-dimensional high resolution sensors. Company's solutions can enable safe autonomy for industries like logistics, drones, robotics, construction and other industrial applications, agriculture, smart city, smart infrastructure, security and mapping.

Share on Social Networks: